Ballentine Partners’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $387K | Buy |
10,729
+2,955
| +38% | +$106K | 0.01% | 579 |
|
|
2025
Q1 | $242K | Sell |
7,774
-72
| -0.9% | -$2.24K | ﹤0.01% | 705 |
|
|
2024
Q4 | $200K | Buy |
+7,846
| New | +$200K | ﹤0.01% | 788 |
|
|
2024
Q2 | – | Sell |
-12,541
| Closed | -$381K | – | 793 |
|
|
2024
Q1 | $381K | Buy |
12,541
+406
| +3% | +$12.3K | 0.01% | 466 |
|
|
2023
Q4 | $341K | Buy |
+12,135
| New | +$341K | 0.01% | 471 |
|
|
2022
Q2 | – | Sell |
-12,932
| Closed | -$504K | – | 475 |
|
|
2022
Q1 | $504K | Buy |
12,932
+3,819
| +42% | +$149K | 0.02% | 255 |
|
|
2021
Q4 | $363K | Buy |
+9,113
| New | +$363K | 0.01% | 334 |
|